Brain and spinal cord cancer testing provider Belay Diagnostics announced on Tuesday that it has partnered with GenomOncology (GO), a precision medicine software company that provides data-driven tools and resources to improve cancer care.

Under the partnership, Belay Diagnostics has incorporated the GO Pathology Workbench into its variant interpretation and analysis workflow to streamline the tertiary analysis of its Summit test and its comprehensive DNA panel. With its tailored clinical applications, the GO Pathology Workbench enables the Belay Diagnostics team to efficiently analyse thousands of samples per month. The customised solution allows the team to make informed variant interpretations and treatment recommendations.

Dr Honey Reddi, PhD, FACMG, senior vice president and medical director at Belay Diagnostics, emphasised the importance of accurate profiling of cerebrospinal fluid (CSF) to inform treatment and management of central nervous system (CNS) cancer, saying: "Our cutting-edge CSF liquid biopsy assay is designed to provide an innovative addition to existing options such as cytology, imaging scans or brain biopsies. Through our collaboration with GenomOncology, we can efficiently reduce laboratory overhead and optimise the review and analysis of our clinical samples. This streamlined process ensures that patients gain quicker access to recommendations, enhancing efficiency in our diagnostic approach."